← Browse by Condition
Medical Condition

mesothelioma

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for mesothelioma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — mesothelioma Clinical Trials

How many clinical trials are currently recruiting for mesothelioma?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for mesothelioma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for mesothelioma?
mesothelioma research spans Phase 1 (3 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a mesothelioma clinical trial?
Eligibility criteria for mesothelioma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
2
Top Sponsors
Oslo University Hospital 1 trial
Dana-Farber Cancer Institute 1 trial
Memorial Sloan Kettering Cancer Center 1 trial
A&G Pharmaceutical Inc. 1 trial
Second Affiliated Hospital of Guangzhou Medical University 1 trial

Recruiting Clinical Trials

NCT02073500
Recruiting
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
Enrollment
300 pts
Location
Norway
Sponsor
Oslo University Hospital
View Trial →
NCT04115254
Recruiting
Stereotactic Magnetic Resonance Guided Radiation Therapy
Enrollment
397 pts
Location
United States
Sponsor
Dana-Farber Cancer Institute
View Trial →
NCT06057935 Phase 2
Recruiting
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Enrollment
64 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT05627960 Phase 1
Recruiting
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Enrollment
77 pts
Location
United States
Sponsor
A&G Pharmaceutical Inc.
View Trial →
NCT06196294 Phase 1
Recruiting
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Enrollment
30 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
NCT06710756 Phase 1, Phase 2
Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Enrollment
112 pts
Location
United States
Sponsor
Perspective Therapeutics
View Trial →

Related Conditions

pancreas cancer (2) lung cancer (2) pseudomyxoma peritonei (1) colorectal carcinoma (1) ovarian carcinoma (1) renal cancer (1) adrenal metastases (1) prostate cancer (1) liver metastases (1) oligoprogressive nodal metastases (1) metachronous nodal metastases (1) synchronous nodal metastases (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology